<DOC>
	<DOCNO>NCT01145976</DOCNO>
	<brief_summary>The purpose study reduce regimen related toxicity transplantation relate mortality allogeneic stem cell transplantation adult acquire aplastic anemia ( AA ) , trial reduce dose Cy along fludarabine ATG performed.11-21 The investigator preliminary data randomize comparison cyclophosphamide plus fludarabine versus cyclophosphamide alone addition anti-thymocyte globulin conditioning therapy allogeneic hematopoietic cell transplantation bone marrow failure syndrome support reduce dose Cy along fludarabine ATG . Conditioning regimen without Cy may reduce RRT Cy-containing conditioning remain several RRT hemorrhagic cystitis , SOS graft versus host disease ( GvHD ) . Recently small trial fludarabine ATG ( Flu-ATG ) condition regimen alloHSCT.22-24 These data raise feasibility fludarabine ATG without Cy patient AA . This new condition regimen Flu-ATG compare standard regimen Cy- ATG randomize control trial .</brief_summary>
	<brief_title>Comparison Cy-Atg v Flu-Atg Conditioning Therapy Allo-HCT Adult Aplastic Anemia</brief_title>
	<detailed_description>TREATMENT PLAN - The patient admit laminar air flow room . - The patient triple lumen Hickman central venous catheter ( CVC ) place . Chest X-ray take CVC placement confirm location CVC absence pneumothorax . - Menstruating woman give norethindrone ( Primolut ) 10 mg po daily . 1 . The preparatory regimen follow : Conditioning therapy start day -5 patient randomized receive Cy+ATG . Hydration 0.45 % NaCl 6 liters/24 hour start day -5 . Cy 50 mg/kg D5W 200 ml i.v . 1-2 hour day -5 -2 pump central venous catheter . Mesna 12 mg/kg iv push immediately Cy 3 , 6 , 9 , 12 hour Cy . Thymoglobuline 3 mg/kg N/S 500-800 mL ( le 0.5 mg/mL ) lymphoglobuline 15 mg/kg N/S 500-800 mL ( le 2 mg/mL ) iv daily 8 day -4 -2 . Premedication ATG ( ALG ) include methylprednisolone 2 mg/kg iv infusion , Tylenol 600 mg po , Avil 45.5 mg iv push . The dos cyclophosphamide ATG ( ALG ) calculate use actual body weight . Conditioning therapy start day -7 patient randomized receive Flu-ATG . Fludarabine 30 mg/m2 infuse intravenously 30 minute D5W 100 ml 6 consecutive day ( day -7 -2 ) . Thymoglobuline 3 mg/kg N/S 500-800 mL ( le 0.5 mg/mL ) lymphoglobuline 15 mg/kg N/S 500-800 mL ( le 2 mg/mL ) iv daily 8 day -4 -2 . Premedication ATG ( ALG ) include methylprednisolone 2 mg/kg iv infusion , Tylenol 600 mg po , Avil 45.5 mg iv push . The dos cyclophosphamide ATG ( ALG ) calculate use actual body weight . 2 . GVHD prophylaxis include cyclosporine plus methotrexate . The patient receive cyclosporine 1.5 mg/kg NS 100 ml i.v . 2-4 hour q 12 hr ( dose cyclosporine round near 5 mg ) start day -1 6 a.m. Cyclosporine dose adjust provide appropriate level accord change renal function ( see Appendix II ) . Cyclosporine dose change oral dose oral feeding become feasible twice i.v . dosage . In addition , patient receive methotrexate 15 mg/m2 i.v . push day 1 10 mg/m2 day 3 , 6 , 11 . The dose methotrexate decrease omit accord guideline provide Appendix III . The dose cyclosporine decrease 10 % every month start day 60 BMT provide clinical evidence GVHD . 3 . Hematopoietic stem cell collection donor . Mobilized peripheral blood stem cell use bone marrow collection case sibling donor permit . Bone marrow collection - Packed red cell 2 unit collect donor autologous transfusion hematopoietic stem cell collection . - Hematopoietic stem cell collect bone marrow appropriate anesthesia . - After collection , Feroba 1T bid give donor 1 month . Mobilized peripheral blood stem cell collection - Recombinant human granulocyte colony-stimulating factor ( G-CSF ) 10 mcg/kg administer sc stem cell donor daily 4 day ( day -3 day 0 ) . - Daily CBC do . - Starting day 4 G-CSF administration ( day 0 ) , peripheral blood mononuclear cell collect leukapheresis CS3000 2 day ( day 0 1 ) . A sample take cell count total cell , mononuclear cell , CD34+ cell , CD3+ cell , CD4+ cell , CD8+ cell . - After sample , final product infused patient immediately day 0 day1 . - At least 2x10^6/kg CD34+ cell collect day 0 . If , additional collection may schedule discretion attend physician . 4.Hematopoietic stem cell infusion - For ABO match minor mismatch transplantation , premedication Avil 45.5 mg i.v . push tylenol 600 mg p.o . give . Stem cell infuse via CVC 1 hr . - For major ABO mismatch transplantation , premedication Avil 45.5 mg i.v . push , tylenol 600 mg p.o. , 10 % mannitol 100 g i.v . 4 hr start 30 min stem cell infusion , hydrocortisone 250 mg i.v . give immediately 30 min stem cell infusion . Stem cell infuse via CVC 1 hour .</detailed_description>
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Anemia , Aplastic</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Vidarabine</mesh_term>
	<criteria>Severe aplastic anemia Severe aplastic anemia ( SAA ) define hypocellular bone marrow ( cellularity &lt; 25 % ) two follow : granulocyte count &lt; 500/ml , platelet count &lt; 20,000/ml , correct reticulocyte count &lt; 1.0 % Very severe aplastic anemia ( VSAA ) define criterion SAA plus granulocyte count &lt; 200/ml Patients 15 year age old , young 65 year . The performance status patient 70 Karnofsky performance scale ( see Appendix I ) . Patients must adequate hepatic function ( bilirubin le 2 mg/dl , AST ALT less three time upper normal limit ) Patients must adequate renal function ( creatinine le 2.0 mg/dl ) . Patients must adequate cardiac function ( ejection fraction &gt; 45 % echocardiogram ) . Exclusion criterion : Patients major illness organ failure . Patients must psychiatric disorder mental deficiency severe make compliance treatment unlikely , make informed consent impossible . Patients must pregnancy . Hypoplastic myelodysplastic syndrome Paroxysmal nocturnal hemoglobinuria</criteria>
	<gender>All</gender>
	<minimum_age>15 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>September 2012</verification_date>
	<keyword>aplastic anemia , fludarabine , cyclophosphamide , thymoglobulin</keyword>
</DOC>